- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00163306
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
Complete Remission: Evaluation of the Complete Remission Rates in Patients With Symptomatic Non-erosive Reflux Disease (NERD) or Erosive Gastroesophageal Reflux Disease (GERD) Treated With Pantoprazole 40 Milligram o.d. Over 4 or 8 or 12 Weeks
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the esophagus. GERD is one of the most common medical disorders, with estimates of up to 50% of adults reporting symptoms related to gastric reflux. Proton pump inhibitors (PPI) such as pantoprazole can relieve symptoms of GERD in a large proportion of patients.
When refluxed stomach acidic content touches the lining of the esophagus, it causes a burning sensation in the chest or throat. This sensation is often referred to as heartburn. Some patients have symptoms of GERD without visible destruction of the tissue surface (no visible changes by endoscopic examination).
The aim of the study is to evaluate the effect of pantoprazole on the complete remission of GERD. Complete remission is defined as endoscopically confirmed healing and symptom relief after a maximum of 12-week treatment period. Pantoprazole will be administered once daily in the morning. Endoscopy will be performed at the start of the study, and then as required after 4, 8, or 12 weeks. The study will provide further data on safety and tolerability of pantoprazole.
Descripción general del estudio
Tipo de estudio
Inscripción
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Amberg, Alemania, 92224
- Altana Pharma/Nycomed
-
Aschersleben, Alemania, 6449
- Altana Pharma/Nycomed
-
Bad Bramstedt, Alemania, 24576
- Altana Pharma/Nycomed
-
Bad Schwalbach, Alemania, 65307
- Altana Pharma/Nycomed
-
Beckum, Alemania, 59269
- Altana Pharma/Nycomed
-
Berlin, Alemania, 10409
- Altana Pharma/Nycomed
-
Berlin, Alemania, 12587
- Altana Pharma/Nycomed
-
Berlin, Alemania, 13581
- Altana Pharma/Nycomed
-
Flensburg, Alemania, 24937
- Altana Pharma/Nycomed
-
Freiburg, Alemania, 79098
- Altana Pharma/Nycomed
-
Freising, Alemania, 85356
- Altana Pharma/Nycomed
-
Germersheim, Alemania, 76726
- Altana Pharma/Nycomed
-
Hamburg, Alemania, 22335
- Altana Pharma/Nycomed
-
Haßfurt, Alemania, 97437
- Altana Pharma/Nycomed
-
Herzogenrath, Alemania, 52134
- Altana Pharma/Nycomed
-
Jülich, Alemania, 52428
- Altana Pharma/Nycomed
-
Kirchheimbolanden, Alemania, 67292
- Altana Pharma/Nycomed
-
Landsberg, Alemania, 6188
- Altana Pharma/Nycomed
-
Langen, Alemania, 63225
- Altana Pharma/Nycomed
-
Leipzig, Alemania, 4105
- Altana Pharma/Nycomed
-
Ludwigsburg, Alemania, 71640
- Altana Pharma/Nycomed
-
Ludwigshafen, Alemania, 67067
- Altana Pharma/Nycomed
-
Lübeck, Alemania, 23569
- Altana Pharma/Nycomed
-
Lütjenburg, Alemania, 24321
- Altana Pharma/Nycomed
-
Magdeburg, Alemania, 39114
- Altana Pharma/Nycomed
-
Magdeburg, Alemania, 39130
- Altana Pharma/Nycomed
-
Mönchengladbach, Alemania, 41239
- Altana Pharma/Nycomed
-
München, Alemania, 80337
- Altana Pharma/Nycomed
-
München, Alemania, 81669
- Altana Pharma/Nycomed
-
Nieder-Olm, Alemania, 55268
- Altana Pharma/Nycomed
-
Oelde, Alemania, 59302
- Altana Pharma/Nycomed
-
Potsdam-Babelsberg, Alemania, 14482
- Altana Pharma/Nycomed
-
Reinfeld, Alemania, 23858
- Altana Pharma/Nycomed
-
Rottweil, Alemania, 78628
- Altana Pharma/Nycomed
-
Saarbrücken, Alemania, 66111
- Altana Pharma/Nycomed
-
Schweinfurt, Alemania, 97421
- Altana Pharma/Nycomed
-
Stuttgart, Alemania, 70565
- Altana Pharma/Nycomed
-
Tessin, Alemania, 18195
- Altana Pharma/Nycomed
-
Wiesbaden, Alemania, 65189
- Altana Pharma/Nycomed
-
Wolfsburg, Alemania, 38448
- Altana Pharma/Nycomed
-
Wolmirstedt, Alemania, 39326
- Altana Pharma/Nycomed
-
-
-
-
-
Deutschlandsberg, Austria, 8539
- Altana Pharma/Nycomed
-
Feldbach, Austria, 8330
- Altana Pharma/Nycomed
-
Graz, Austria, 8010
- Altana Pharma/Nycomed
-
Graz, Austria, 8020
- Altana Pharma/Nycomed
-
Krems a. d. Donau, Austria, 3500
- Altana Pharma/Nycomed
-
Lilienfeld, Austria, 3180
- Altana Pharma/Nycomed
-
Stockerau, Austria, 2000
- Altana Pharma/Nycomed
-
Wien, Austria, 1130
- Altana Pharma/Nycomed
-
Wien, Austria, 1140
- Altana Pharma/Nycomed
-
Wien, Austria, 1170
- Altana Pharma/Nycomed
-
Wiener Neustadt, Austria, 2700
- Altana Pharma/Nycomed
-
-
-
-
-
Budapest, Hungría, 1085
- Altana Pharma/Nycomed
-
Budapest, Hungría, 1032
- Altana Pharma/Nycomed
-
Budapest, Hungría, 1062
- Altana Pharma/Nycomed
-
Budapest, Hungría, 1115
- Altana Pharma/Nycomed
-
Gyula, Hungría, 5700
- Altana Pharma/Nycomed
-
Györ, Hungría, 9024
- Altana Pharma/Nycomed
-
Hatvan, Hungría, 3000
- Altana Pharma/Nycomed
-
Kaposvár, Hungría, 7400
- Altana Pharma/Nycomed
-
Miskolc, Hungría, 3526
- Altana Pharma/Nycomed
-
Pécs, Hungría, 7632
- Altana Pharma/Nycomed
-
Szeged, Hungría, 6720
- Altana Pharma/Nycomed
-
Szekesfehervar, Hungría, 8000
- Altana Pharma/Nycomed
-
Szekszárd, Hungría, 7100
- Altana Pharma/Nycomed
-
Szentes, Hungría, 6600
- Altana Pharma/Nycomed
-
Szombathely, Hungría, 9701
- Altana Pharma/Nycomed
-
Tatabanya, Hungría, 2800
- Altana Pharma/Nycomed
-
Vác, Hungría, 2601
- Altana Pharma/Nycomed
-
-
-
-
-
Bydgoszcz, Polonia, 85-168
- Altana Pharma/Nycomed
-
Drezdenko, Polonia, 66-530
- Altana Pharma/Nycomed
-
Kielce, Polonia, 25-513
- Altana Pharma/Nycomed
-
Kraków, Polonia, 31-153
- Altana Pharma/Nycomed
-
Rzeszow, Polonia, 35-068
- Altana Pharma/Nycomed
-
Rzeszow, Polonia, 35025
- Altana Pharma/Nycomed
-
Slupsk, Polonia, 76200
- Altana Pharma/Nycomed
-
Sopot, Polonia, 81-756
- Altana Pharma/Nycomed
-
Torun, Polonia, 87-100
- Altana Pharma/Nycomed
-
Tychy, Polonia, 43-100
- Altana Pharma/Nycomed
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Main Inclusion Criteria:
- Outpatients
- Reflux disease-related symptoms for at least 12 weeks, which need not be consecutive, in the previous 12 months or endoscopically confirmed reflux esophagitis grade A to D, according to LA-classification
Main Exclusion Criteria:
- Regular intake of systemic glucocorticosteroids, NSAIDs including COX-2 inhibitors on >3 consecutive days per week within the previous 28 days; exception: regular intake of acetylsalicylic acid up to a daily dose of 150 mg/day
- Intake of PPIs (proton pump inhibitor) during the last 10 days, of histamine 2-receptor antagonists or prokinetics during the last 5 days, intake of sucralfate during the last 2 days before the start of the study
- Intake of PPIs in combination with antibiotics for eradication of H. pylori during the last 28 days prior to study start
- Eradication of H. pylori during the last 28 days prior to study start
- Acute peptic ulcer and/or ulcer complications
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
---|
complete reflux disease remission rate after 8 weeks of treatment defined as symptom relief assessed by reflux questionnaire (ReQuest Trademark) and endoscopically confirmed healing.
|
Medidas de resultado secundarias
Medida de resultado |
---|
complete reflux disease remission rates after 4, 8, and 12 weeks
|
time to reach first complete remission
|
time to reach sustained complete remission
|
time to reach first symptom relief that is based on the pre-defined GERD symptoms threshold of the reflux questionnaire
|
average symptom load above pre-defined GERD symptoms threshold
|
relief rates from reflux disease related complaints after 4, 8 and 12 weeks
|
endoscopically confirmed healing rates after 4, 8, and 12 weeks
|
symptom relief rates after 4, 8 and 12 weeks
|
influence of the H. pylori status on the complete reflux disease remission rate
|
influence of the H. pylori status on the symptom relief rates
|
influence of the H. pylori status on the endoscopically confirmed healing rates.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Hartmut Heinze, MD, Altana Pharma AG, D-78467 Konstanz, Germany, info.clintrials@altanapharma.com
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Enfermedades del Estómago
- Gastroenteritis
- Enfermedades intestinales
- Trastornos de la motilidad esofágica
- Trastornos de la deglución
- Enfermedades esofágicas
- Esofagitis
- Úlcera péptica
- Enfermedades Duodenales
- Reflujo gastroesofágico
- Esofagitis Péptica
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes Gastrointestinales
- Agentes Antiulcerosos
- Inhibidores de la bomba de protones
- Pantoprazol
Otros números de identificación del estudio
- BY1023/M3-339
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Pantoprazol
-
Alexandria UniversityTerminadoHipertensión portal | Hemorragia Variceal | Hemorragia ulcerosaEgipto
-
University of Auckland, New ZealandTerminadoCáncer de mama | Náuseas y vómitos inducidos por quimioterapia | OncologíaNueva Zelanda
-
Kwong Wah HospitalTerminadoHemorragia por úlcera pépticaPorcelana
-
TakedaRetiradoControl de pH gástricoMéxico
-
PfizerReclutamientoEsofagitisBélgica, Estados Unidos, Reino Unido, Serbia, Georgia, Hungría, Bosnia y Herzegovina, Puerto Rico, Pavo, Eslovaquia, India
-
Wyeth is now a wholly owned subsidiary of PfizerTerminadoReflujo gastroesofágico
-
PfizerTerminadoLa enfermedad por reflujo gastroesofágicoEstados Unidos, Bosnia y Herzegovina, Eslovaquia, Italia, Alemania, Argentina, Georgia, Serbia, Ucrania
-
Emory UniversityWyeth is now a wholly owned subsidiary of PfizerTerminado
-
McMaster UniversityCanadian Institutes of Health Research (CIHR)TerminadoHemorragia GastrointestinalCanadá